Progenics Pharmaceuticals Comments on Velan Capital’s Preliminary Proxy Statement
07 mai 2019 16h15 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, May 07, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX, “Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial...
Progenics Pharmaceuticals Issues Statement Regarding Velan Capital
06 mai 2019 16h15 HE
|
Progenics Pharmaceuticals Inc.
Progenics Board Deeply Committed to Enhancing Value for all Shareholders Repeated Efforts to Engage Meaningfully with Velan Rebuffed No Shareholder Action Required at this Time NEW YORK, May 06,...
Data Presented at the 2019 American Urological Association (AUA) Annual Meeting Showcases Potential for Progenics’ PyL Imaging Agent
06 mai 2019 08h30 HE
|
Progenics Pharmaceuticals Inc.
-Phase 2/3 OSPREY Data Demonstrates PyL’s High Specificity and Sensitivity in Detecting Prostate Cancer- -Data Generated Under PyL Research Access Program Supports Potential of PyL to Detect Disease...
Progenics Pharmaceuticals Sets First Quarter 2019 Financial Results and Business Update Call for May 9
02 mai 2019 08h30 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, May 02, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...
Results from Clinical Trial Show Progenics’ PyL (18F-DCFPyL) PSMA PET/CT Imaging Agent Changes Management Plans for More Than 87% of Patients
24 avr. 2019 08h30 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, April 24, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find,...
Progenics Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference
03 avr. 2019 17h05 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, April 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight...
Progenics Pharmaceuticals Announces Presentations at the 2019 American Urological Association (AUA) Annual Meeting
03 avr. 2019 17h00 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, April 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight...
Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2018 Financial Results and Business Update
14 mars 2019 07h45 HE
|
Progenics Pharmaceuticals Inc.
AZEDRA® (iobenguane I 131) U.S. Commercial Launch – 14 Treatment Requests from Patients Have Been Received and Scheduling for those Patients is Underway; 8 Centers Throughout the U.S. are Ready to...
Progenics Asserts Ownership of PSMA-617 Intellectual Property, Including Composition of Matter Patent
14 mars 2019 07h40 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, March 14, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company focused on the development and commercialization of innovative targeted medicines and...
Progenics Pharmaceuticals Announces Presentation of Safety Data for AZEDRA® (iobenguane I 131) at the 2019 Endocrine Society (ENDO) Annual Meeting
11 mars 2019 08h30 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, March 11, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and...